DiaMedica Therapeutics Inc. Share Price & Technical Analysis
DMAC · $5.91 (+2.43%)
Healthcare / Biotechnology
$5.91
+2.43%
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal …
Price chart
Seasonality
May has 3 positive and 1 negative years (last 5 years shown)
-2% return in May, 23% avg return in past 3 year May month.
-27% return in 2026, 72% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -1% | -1% | -13% | -10% | -2% | – | – | – | – | – | – | – | -27% |
| 25 | 5% | 14% | -42% | 11% | 0% | -5% | 8% | 36% | 21% | 4% | 21% | -7% | 66% |
| 24 | 0% | 3% | -7% | -7% | 12% | 3% | 10% | 11% | 5% | 5% | 30% | 0% | 65% |
| 23 | -12% | 21% | -12% | 7% | 59% | 54% | -21% | -12% | -13% | -12% | 9% | 17% | 84% |
| 22 | -32% | 0% | -4% | -8% | 4% | -17% | -20% | 13% | -33% | 0% | 0% | 33% | -63% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Uptrend
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$334.88M
P/E ratio
—
52W high
$10.42
52W low
$3.48
Volume
87,853
Beta
0.99
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is DiaMedica Therapeutics Inc. share price today?
- DiaMedica Therapeutics Inc. (DMAC) last traded around $5.91 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does DMAC have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for DMAC. Download the app for real-time alerts.
- How can I analyze DiaMedica Therapeutics Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.